Equity Overview
Price & Market Data
Price: $20.21
Daily Change: -$0.82 / 4.06%
Range: $20.00 - $21.91
Market Cap: $2,268,996,864
Volume: 497,783
Performance Metrics
1 Week: 0.35%
1 Month: 7.79%
3 Months: -13.52%
6 Months: -22.83%
1 Year: 1.76%
YTD: -21.36%
Company Details
Employees: 68
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Netherlands
Details
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.